ADT and Cognition: Vortioxetine Shows a Targeted Effect in Animals
On October 5, 2026, UT Health San Antonio reported animal-model findings in which vortioxetine improved cognitive impairment associated with androgen-deprivation therapy (ADT). David Morilak, PhD, led the research and directs the university’s Center for Biomedical Neuroscience.
Inside the research
The university’s report describes a series of animal models designed to separate several possible sources of cognitive impairment. The researchers examined androgen deprivation, aging and the effects of prostate tumors. This design matters because a change in cognition during cancer care may have more than one explanation.
ADT is a prostate-cancer treatment that blocks testosterone. Vortioxetine is an FDA-approved antidepressant that acts on several serotonin receptors. The team’s question was whether this existing drug could address cognitive impairment associated with androgen deprivation.
One model used older animals about 14 months old. The university estimates that this is roughly equivalent to the late 50s or early 60s in humans. A separate prostate-tumor model included treatment with degarelix, allowing the researchers to examine tumor-related and treatment-related effects separately.
The report describes cognition in terms of cognitive flexibility, memory and spatial navigation. It identifies the ventromedial prefrontal cortex and hippocampus as the brain areas of interest. It does not state how long the animal experiments lasted.
The reported outcomes
UT Health San Antonio describes a pattern of results that varied with the source of impairment:
- Initial androgen-deprivation model: Androgen deprivation produced cognitive deficits. Vortioxetine reversed those effects.
- Older-animal model: ADT worsened impairment in the older animals. Vortioxetine improved the therapy-related impairment but did not affect their natural age-related cognitive decline.
- Tumor-related impairment: The cancer itself affected cognition. Vortioxetine did not reverse that effect.
- Treatment in tumor-bearing animals: In animals whose tumors were treated with degarelix, the university reports that vortioxetine resolved the resulting cognitive impairment.
- Anticancer effectiveness: Follow-up animal studies found that vortioxetine did not interfere with ADT’s effectiveness against cancer, according to the university report.
The useful signal is the separation between causes. The drug’s effect was not uniform across every kind of cognitive impairment examined. That makes this a focused research lead about androgen deprivation rather than a broad claim about better memory.
For men following research on mental performance, this distinction is the central point. A finding becomes more useful when the researchers identify the particular problem it addresses rather than treating all cognitive change as one condition.
A possible mechanism
Morilak suggests that vortioxetine’s action on multiple receptors may restore neuroplasticity. The university describes neuroplasticity as the brain’s ability to change. His team is investigating which receptor targets may be responsible.
That explanation remains a hypothesis under investigation. The reported improvement and the proposed mechanism are separate parts of the story: observing an effect does not establish exactly how the effect occurred.
This is a useful distinction when reading drug research. The immediate finding concerns performance in the reported models. The receptor work asks why that finding might occur and whether it can guide further research.
The clinical context
A 2026 review of cancer therapy-related cognitive impairment adds context from research involving patients. It describes worsening self-reported cognition during ADT and related therapies. It also notes that a substantial proportion of patients already had objective cognitive impairment before treatment.
A report of poorer mental clarity and a change on formal testing are related observations, but they are not the same measurement. The review’s account supports taking both seriously without assuming they will always match. It also cautions against assuming that every difficulty noticed during treatment began with treatment.
In one prospective cohort discussed in the review, more than 90% of participants had stable or minimally changed objective cognitive performance during follow-up. These participants were older men with metastatic castration-resistant prostate cancer receiving commonly used systemic therapies. A small minority had notable decline, without a clear treatment-specific pattern.
That result applies to the cohort described. It is not a percentage that can be assigned to all men receiving ADT or used to dismiss an individual man’s symptoms.
The review also describes plausible biological pathways. ADT reduces circulating testosterone and downstream oestradiol, with possible effects on brain plasticity and inflammation. It also discusses vascular-metabolic function as part of this picture.
Long-term dementia risk with prolonged ADT is a separate question from short-term changes on cognitive tests, the review notes. Keeping those outcomes apart prevents a discussion about mental clarity from becoming an unsupported prediction about dementia.
Limits that matter
The university report does not provide animal sample sizes, detailed protocols, named cognitive tests or statistical results. Those omissions prevent an independent assessment of the size and reliability of the findings from this account alone.
No human clinical-trial outcomes are reported. The article therefore does not establish vortioxetine’s safety or effectiveness for ADT-related cognitive impairment in men with prostate cancer. Its existing approval as an antidepressant does not settle that separate clinical question.
Morilak says trials of already-approved drugs can move more quickly. That makes further testing the relevant next research step.
The report also does not establish a specific exercise, supplement or cognitive-training program as a remedy for this problem. Broader reading on physical activity and cognitive aging should be kept separate from evidence about this drug and treatment setting.
Quality of life
Morilak frames the work around life after treatment: “It becomes not just about treating the cancer but about managing quality of life after cancer treatment.”
For a man receiving ADT, changes in memory, attention or mental clarity belong in a conversation with his oncology team. The evidence supports raising the concern without deciding in advance that ADT is the only cause. It also argues against brushing aside a symptom simply because formal test results may look different from personal experience.
The practical issue is how to make that conversation useful. Describing the change and asking how it should be assessed keeps the focus on the person’s experience and clinical context. It does not require arriving with a medication already chosen.
Decisions about changing cancer treatment or adding another medication belong with qualified clinicians. This research is a lead for further investigation, not a reason for self-treatment.
What this changes: the findings sharpen a question for human trials and reinforce attention to quality of life, but they do not justify changing current clinical practice.
How Everfitguys helps
Deciding how much weight to give this antidepressant finding requires separating a research lead from a treatment option, the editorial task Everfitguys takes on. The publication examines evidence on cognitive performance and healthy aging for men after 45 who value mental sharpness and continued independence.
Sources
Stay sharp
Get stories
The best writing on craft and life, delivered once a week. No noise, just the good stuff.
